Cellular Biomedicine Group Inc. , a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases, today announced clinical data from its CAR-T immuno-oncology clinical development programs. The data will be discussed by Dr. Wei Cao, PhD, BM, Chief Executive Officer of Cellular Biomedicine Group, at the 2015 Annual Regen Med Investor Day on March 25 in New York City.
http://ift.tt/1IuMyZT
http://ift.tt/1IuMyZT
No comments:
Post a Comment